Good news for advanced therapies, bad news for an old painkiller
This article was originally published in Scrip
It's been a busy week for the European Medicines Agency. Not only has it recommended marketing approval of the first advanced therapy product under the new regulatory framework, it has also finally decided that all drugs containing the opioid painkiller dextropropoxyphene should be withdrawn for safety reasons.
You may also be interested in...
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.
Russia’s new drug traceability system won’t now be implemented until July, but companies that are ready and able are being encouraged to put the system through its paces in order to flush out any glitches.